Drug Trial Radar · NCT07843459
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
111
Planned (sponsor's estimate)
Start
Oct 7, 2026
Primary completion
Jul 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Sep 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to see how safe LY4560736 is and to see how much and how quickly LY4560736 gets into the bloodstream. For healthy participants, the study also looks at how much LY4560736 gets into the brain. This part of the study lasts up to 13 weeks which includes staying in the Clinical Research Unit (CRU) for at least 4 days. This group will include Japanese participants, and the Sponsor may choose to enroll Chinese participants. For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 13 weeks which includes staying in the CRU twice, each lasts about 1 to 2 days. Japanese participants, and potentially Chinese participants, may also be enrolled in this group.
Conditions
- Healthy Volunteers
- Alzheimer Disease
- Amyloid
- Plaque, Amyloid
- Plasma
Interventions
LY4560736Drug
Administered intravenously (IV)
LY4560736Drug
Administered subcutaneously (SC)
PlaceboDrug
Administered IV
PlaceboDrug
Administered SC
Florbetapir F18Other
Administered IV
Florbetaben F 18Other
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline up to 13 Weeks
Locations
19 sites in 3 countries. Site status is shown where the registry gives one.
CenExel ACT
Anaheim, California · Recruiting
Irvine Clinical Research
Irvine, California · Not yet recruiting
Collaborative Neuroscience Network - CNS
Los Alamitos, California · Recruiting
Fortrea Clinical Research Unit
Daytona Beach, Florida · Recruiting
K2 Medical Research - The Villages
Lady Lake, Florida · Not yet recruiting
K2 Medical Research
Maitland, Florida · Not yet recruiting
Charter Research
Orlando, Florida · Not yet recruiting
Progressive Medical Research
Port Orange, Florida · Not yet recruiting
Alzheimer's Research and Treatment Center
Stuart, Florida · Not yet recruiting
K2 Medical Research - Tampa
Tampa, Florida · Not yet recruiting
Charter Research
The Villages, Florida · Not yet recruiting
Accel Research Sites - NeuroStudies Clinical Research Unit
Decatur, Georgia · Not yet recruiting
QUEST Research Institute
Farmington Hills, Michigan · Not yet recruiting
Xuanwu Hospital Capital Medical University
Beijing, China · Not yet recruiting
Peking University Third Hospital
Beijing, China · Not yet recruiting
Huashan Hospital, Fudan University
Minhang District, China · Not yet recruiting
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China · Not yet recruiting
The University of Tokyo Hospital
Bunkyō City, Japan · Not yet recruiting
National Center for Geriatrics and Gerontology
Ōbu, Japan · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.